Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial
Hites et al., Journal of Infection, doi:10.1016/j.jinf.2024.106120
https://c19early.org/hites.html